Brokerages expect that SI-Bone Inc (NASDAQ:SIBN) will report ($0.20) earnings per share for the current quarter, Zacks reports. Zero analysts have provided estimates for SI-Bone’s earnings. The firm is expected to issue its next quarterly earnings results on Thursday, March 7th.
On average, analysts expect that SI-Bone will report full-year earnings of ($0.64) per share for the current year, with EPS estimates ranging from ($0.88) to ($0.39). For the next fiscal year, analysts forecast that the company will report earnings of ($0.80) per share, with EPS estimates ranging from ($0.82) to ($0.77). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that follow SI-Bone.
SI-Bone (NASDAQ:SIBN) last announced its earnings results on Thursday, November 29th. The company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.03). The business had revenue of $13.38 million during the quarter.
In other SI-Bone news, major shareholder Skyline Venture Partners V. Lp acquired 325,000 shares of the business’s stock in a transaction on Friday, October 19th. The stock was bought at an average price of $15.00 per share, for a total transaction of $4,875,000.00. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director David P. Bonita acquired 200,000 shares of the business’s stock in a transaction on Friday, October 19th. The stock was acquired at an average price of $15.00 per share, with a total value of $3,000,000.00. The disclosure for this purchase can be found here.
NASDAQ SIBN traded down $0.21 on Friday, hitting $21.38. The company’s stock had a trading volume of 37,194 shares, compared to its average volume of 80,612. SI-Bone has a 52-week low of $16.27 and a 52-week high of $21.96.
SI-Bone Company Profile
SI-BONE, Inc, a medical device company, develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. It offers iFuse, an implant system to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. The company was founded in 2008 and is headquartered in Santa Clara, California.
See Also: Balanced Fund
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for SI-Bone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SI-Bone and related companies with MarketBeat.com's FREE daily email newsletter.